This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Experienced interventional radiologists to provide medical and technical advice to treatment users
June 5, 2012 /PRNewswire/ - Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced the launch of a new preceptor program to support doctors using TheraSphere
®, the company's
Yttrium-90 (Y-90) glass microsphere liver cancer treatment.
Matthew Johnson, MD, Professor of Radiology and Surgery at the
Indiana University School of Medicine in
Siddharth Padia, MD, Assistant Professor of Interventional Radiology at the
University of Washington in Seattle, are both highly experienced TheraSphere
® users, having between them administered more than 1,000
Y-90 radioembolization treatments. As preceptors, they will help guide and coach physicians at various stages of TheraSphere
® clinical use.
"Nordion wants to help physicians develop a solid technical foundation for treating hepatocellular carcinoma with TheraSphere
Mason Ross, MD, Nordion's VP of Medical Affairs. "This program is designed to assist doctors to make independent decisions with confidence about the use and administration of TheraSphere
®. With the training programs at our Centers of Excellence in the US and
Europe, our technical proctors and these new physician preceptors, Nordion now offers end-to-end training and support for physicians in the use of Therasphere
®, whether it's their first dose or their 100
The preceptors will provide medical and technical advice to physicians using TheraSphere
®. Their role includes:
Advising peers on appropriate patient selection and screening
Reviewing imaging scans of potential patients
Providing guidance on treatment planning
Reviewing dosimetry and dose selection considerations for specific patients
Advising on treatment administration techniques
Providing post-treatment guidance
"Because the availability of
Y-90 therapy is relatively recent, it's critical for physicians to be able to leverage and share experience and best practices," said Dr. Johnson. "I'm pleased that Nordion has recognized this and is establishing this forum."
The preceptors will be available by email and are committed to providing timely responses to questions from physicians.